YSYeeun Sun

Yeeun Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yeeun Sun has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progressive Ataxia With Palatal Tremor in a Patient Carrying the Prion Protein Gene M232R Variation: A Case Report

    by Hak-Loh Lee, Yeeun Sun, Han Kyu Na, Seok Jong Chung, Phil Hyu Lee

    Progressive ataxia with palatal tremor in a patient carrying the prion protein gene M232R variation: a case report

  • Open Access

    Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease

    by Han Kyu Na, Yeeun Sun, Chan Wook Park, Jung Hyun Lee, Yun Young Choi, Quynh Phuong Vo, Seok Jong Chung, Han Soo Yoo, Chul Hyoung Lyoo, Young H. Sohn, et al.

    Background: Concurrent Alzheimer's disease pathology is increasingly recognized as a poor prognostic factor in Parkinson's disease (PD), yet reliable clinical indicators for early identification of AD copathology remain poorly established. Objective: To investigate baseline motor and nonmotor symptom profiles associated with amyloid‐β (Aβ) copathology in newly diagnosed PD. Methods: Among patients with PD who underwent Aβ imaging, we retrospectively identified 152 patients who completed the Cross‐Cultural Smell Identification Test (CC‐SIT), autonomic function tests, neuropsychological assessment, and Neuropsychiatric Inventory Questionnaire (NPI‐Q) at drug‐naive state. Predictors of Aβ positivity were identified using stepwise multivariable logistic regression and validated with Random Forest classifiers employing Boruta feature selection. Results: Compared with Aβ‐negative counterparts (n = 93), Aβ‐positive (Aβ + PD, n = 59) patients demonstrated greater olfactory dysfunction (CC‐SIT, P = 0.002), dysautonomia (Composite Autonomic Severity Scale [CASS], P < 0.001), and mood disturbance (NPI‐Q‐mood, P < 0.001) and higher prevalence of probable rapid eye movement sleep behavior disorder ( P = 0.009) and neurogenic orthostatic hypotension ( P = 0.006). Aβ + PD patients showed greater motor disability (Unified Parkinson's Disease Rating Scale Part III [UPDRS‐III], P < 0.001) despite comparable striatal dopamine transporter uptake. Logistic regression identified lower CC‐SIT scores (odds ratio [OR] = 0.821, 95% confidence interval [CI 95% ]: 0.703–0.959), higher CASS scores (OR = 1.380, CI 95% : 1.144–1.666), higher NPI‐Q‐mood scores (OR = 1.057, CI 95% : 1.005–1.111), higher UPDRS‐III (OR = 1.080, CI 95% : 1.030–1.132), and APOE ε4 carrier status (OR = 3.643, CI 95% : 1.479–8.969) as independent predictors of Aβ positivity, which were also confirmed as important variables by Boruta feature selection. Conclusions: Our findings suggest that greater motor and nonmotor symptom burden at diagnosis, characterized by olfactory/autonomic dysfunction, mood disturbance, and motor deficits disproportionate to dopaminergic denervation, was associated with Aβ positivity in PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Spatiotemporal Progression Patterns of Striatal Dopamine Depletion and Cerebral Hypoperfusion in Parkinson's Disease

    by Yeeun Sun, Youngseok Choi, Chan Wook Park, Han Kyu Na, Hye Sun Lee, Yun Joong Kim, Young H. Sohn, Phil Hyu Lee, Jeyeon Lee, Seok Jong Chung

    Background: The identification of Parkinson's disease (PD) subtypes is crucial for predicting the disease course and designing personalized therapeutic strategies. Objectives: The aim of the study was to characterize the heterogeneity of the spatiotemporal evolutionary patterns of striatal dopamine depletion and cerebral hypoperfusion in PD. Methods: We retrospectively enrolled 708 patients with newly diagnosed PD and 50 healthy controls who underwent dual‐phase 18 F‐FP‐CIT PET scans. We applied subtype and stage inference (SuStaIn) to delineate three PD subtypes after quantifying the dual‐phase 18 F‐FP‐CIT PET data. We compared the baseline clinical features as well as the longitudinal motor and cognitive outcomes between subtypes. Results: Subtype 1 (n = 406) initially presented with asymmetric dopamine loss in the posterior putamen, followed by dopaminergic deficits in other striatal subregions and, later, cerebral hypoperfusion. Subtype 2 (n = 205) exhibited diffuse and symmetric striatal dopamine loss in the early stages, followed by cerebral hypoperfusion in the mid‐stages. Subtype 3 (n = 89) initially showed the parieto‐occipital hypoperfusion, followed by cerebral hypoperfusion in other cortical areas and striatal dopamine depletion. Subtype 2 had an older age of onset, and subtype 3 had a younger age of onset and a lower prevalence of rapid eye movement sleep behavior disorder. Time‐dependent Cox regression models showed that the risk of dementia conversion within a follow‐up period of 4 years was higher in subtypes 2 and 3 (hazard ratios 1.772 and 2.802, respectively) than subtype 1, after the confounding effects were adjusted. The risk of developing levodopa‐induced dyskinesia and freezing of gait was comparable between subtypes. Conclusions: The spatiotemporal trajectories of striatal dopamine depletion and cerebral hypoperfusion on dual‐phase 18 F‐FP‐CIT PET images could serve as a potential progression marker for cognitive decline in early‐stage PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Cerebral Perfusion and Motor Deficits in Drug-Induced Parkinsonism

    by Yeeun Sun, Han Kyu Na, Seun Jeon, Byoung Seok Ye, Phil Hyu Lee, Han Soo Yoo, Chul Hyoung Lyoo

    Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after Parkinson disease (PD). It is crucial to diagnose DIP in patients presenting with parkinsonian symptoms because discontinuation of the offending drug can improve parkinsonism. However, the detailed pathophysiology of parkinsonism related to striatal dopamine receptor blockade and disease-specific cerebral changes remains unclear. In this cross-sectional study, we recruited patients with DIP who underwent the Unified Parkinson's Disease Rating Scale (UPDRS) assessment, brain MRI, and dual-phase 18F-FP-CIT PET. The offending drugs were gastrointestinal prokinetics (DIPGI) and antipsychotics (DIPAP). In addition, we enrolled early and drug-naïve patients with PD and healthy controls (HCs). We compared early-phase 18F-FP-CIT uptakes between DIP, PD, and HC groups and investigated its association with the UPDRS part III total score. We calculated the DIP-related perfusion patterns using W-scores, compared their expression among groups, and analyzed their diagnostic performance. Age at PET scan, sex, and vascular risk factors were included as covariates. Compared with patients with PD (n = 160, mean age 68.9 ± 7.9 years; 74 men), the DIP group (n = 72, mean age 67.9 ± 12.9 years; 25 men) exhibited more profound hyperperfusion in the motor-related brain circuit and prominent hypoperfusion in widespread brain regions except for the occipital cortex than HCs (n = 62, mean age 66.9 ± 9.0 years; 25 men). In particular, the DIPGI group (n = 23) showed relative hypoperfusion in the lateral prefrontal, insular, inferior parietal, and cingulate cortices. In the DIP group, UPDRS part III total score was not correlated with striatal dopamine deficits but was associated with the degree of relative perfusion in the prefrontal, insular, and cingulate cortices. By contrast, the UPDRS part III total score in the PD group was not correlated with cerebral perfusion but was associated with striatal dopamine depletion, especially in the posterior putamen. The DIP-related cerebral perfusion pattern effectively discriminated patients with DIP from HCs and patients with PD. Blockage of dopamine receptors by drugs is associated with characteristic cerebral perfusion patterns that are distinct from those in patients with PD and correlate with symptom severity.


  • Open Access

    Olfactory Dysfunction as a Window Into the Heterogeneity of Parkinson Disease

    by Yeeun Sun, Han Kyu Na, So Hoon Yoon, Quynh Phuong Vo, Chan Wook Park, Jung Hyun Lee, Yun Young Choi, Han Soo Yoo, Young H. Sohn, Chul Hyoung Lyoo, et al.

    Background: While olfactory dysfunction is common in Parkinson disease (PD), its neural basis and clinical implications remain to be clarified. We investigated the neural substrates and clinical profiles, particularly non‐motor symptoms (NMSs), associated with olfactory function. Methods: This retrospective study included 259 drug‐naïve patients with PD who underwent the Cross‐Cultural Smell Identification Test (CC‐SIT), comprehensive autonomic function test, neuropsychological assessments, and the Neuropsychiatric Inventory Questionnaire (NPI‐Q) at diagnosis. NMS profiles were compared across olfactory groups defined by CC‐SIT scores (normosmia [ n = 45], hyposmia [ n = 143], anosmia [ n = 74]). Associations between olfaction and clinical/imaging variables were assessed using correlation and path analyses. Cox proportional hazards models were employed to evaluate the risk of developing motor complications or PD dementia according to olfactory status. Results: CC‐SIT scores correlated with Composite Autonomic Severity Scale scores (rho = −0.219, p = 0.001), NPI‐Q scores (rho = −0.269, p < 0.001), and cognitive performance in memory (rho = 0.288, p < 0.001) and frontal/executive domains (rho = 0.205, p = 0.001). Dopaminergic depletion in the caudate nucleus and limbic atrophy emerged as neural substrates underlying olfactory dysfunction, mediating the association between olfaction and cognitive/neuropsychiatric symptoms. Anosmia was associated with increased risk of developing PD dementia compared to normosmia (hazard ratio [HR]: 2.579; 95% confidence intervals [CI]: 1.137–5.851) and hyposmia (HR: 2.783; 95% CI: 1.437–5.390). Anosmia was associated with higher risk of developing freezing of gait (HR: 2.571; 95% CI: 1.077–6.134) compared to normosmia. Conclusions: Olfactory dysfunction serves as a multifaceted clinical marker associated with convergent degeneration of nigrostriatal and limbic pathways, offering insights into PD phenotypic variance and its prognostic implications.